The Medicines Company (NASDAQ:MDCO)

CAPS Rating: 5 out of 5

A pharmaceutical company provides innovative, cost effective acute care hospital products to the worldwide hospital marketplace.

Caps

How do you think MDCO will perform against the market?

Add Stock to CAPS Watchlist

All Players

179 Outperform
16 Underperform
 

All-Star Players

51 Outperform
2 Underperform
 

Wall Street

8 Outperform
1 Underperform
 

Top MDCO Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.77)
Submitted May 26, 2013

I've watched Medicines' ascent from the sidelines but after reviewing the stock again this week I've decided to follow the story more closely with a green thumb. Angiomax revenues have remained solid, although I'm concerned regarding ongoing… More

agard43 (< 20)
Submitted March 23, 2007

TheStreet.com: "There still seems to be a lot of hope built into the stock price. As Morgan Stanley analyst Stephen Herr wrote this week, "if the patent life is not extended, this stock looks broadly overvalued."

MDCO VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about MDCO.

Recs

0
Member Avatar km00nster (< 20) Submitted: 3/17/2017 11:32:18 PM : Outperform Start Price: $48.76 MDCO Score: -23.41

buy the dip, great results on it's onion 1 drug. a take out target

Recs

0
Member Avatar EvanBuck (99.90) Submitted: 9/2/2013 1:46:32 PM : Outperform Start Price: $26.06 MDCO Score: -30.80

zzlangerhans

Recs

4
Member Avatar zzlangerhans (99.77) Submitted: 5/26/2013 2:25:22 AM : Outperform Start Price: $33.82 MDCO Score: -29.91

I've watched Medicines' ascent from the sidelines but after reviewing the stock again this week I've decided to follow the story more closely with a green thumb. Angiomax revenues have remained solid, although I'm concerned regarding ongoing litigation with generic manufacturers. Regardless, the drug will only maintain exclusivity through 2019 due to agreements with Teva and Fresenius. However, the company has now produced a second act for the near term in the form of cangrelor, which recently showed strong superiority to Plavix in the CHAMPION PHOENIX trial. The company is also broadening their approach by inlicensing ALN-PCS RNAi from Alnylam and purchasing Incline Therapeutics and their Ionsys pain platform. I'm more skeptical about oritavancin, an antibiotic whose prospects failed to keep developer Targanta from being absorbed for a pittance. Nevertheless, positive phase III data from the SOLO-2 trial could give the stock a boost in mid 2013.

Leaderboard

Find the members with the highest scoring picks in MDCO.

Score Leader

trossman

trossman (65.04) Score: +331.51

The Score Leader is the player with the highest score across all their picks in MDCO.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
trossman 65.04 5/15/2009 Outperform 3M $6.35 +508.11% +176.60% +331.51 0 Comment
535710 < 20 5/3/2010 Outperform 5Y $7.37 +423.74% +103.66% +320.08 0 Comment
LimitedRisk < 20 5/10/2010 Outperform 5Y $7.40 +421.62% +109.94% +311.68 0 Comment
04263010 < 20 4/26/2010 Outperform 5Y $7.91 +387.99% +99.53% +288.46 0 Comment
MA90250 < 20 3/29/2010 Outperform 5Y $7.90 +388.61% +107.50% +281.11 0 Comment
3294210 < 20 3/29/2010 Outperform 5Y $7.90 +388.61% +107.50% +281.11 0 Comment
jmwcubed < 20 5/19/2009 Outperform 3M $7.03 +449.08% +168.25% +280.83 0 Comment
RockEmSockEm < 20 3/24/2010 Outperform 5Y $7.93 +386.76% +107.86% +278.90 0 Comment
OnlyOptionable < 20 3/25/2010 Outperform 5Y $8.00 +382.50% +106.69% +275.81 0 Comment
ZOPS13 < 20 4/5/2010 Outperform 5Y $8.02 +381.30% +105.61% +275.69 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackCreditSuiss 91.35 11/20/2014 Outperform NS $25.90 +49.03% +19.03% +30.01 0 Comment
trackisigroup 73.69 1/3/2013 Outperform NS $24.82 +55.52% +66.54% -11.02 0 Comment
TrackOppenheimer 72.00 11/20/2012 Outperform NS $21.63 +78.46% +75.03% +3.43 0 Comment
TrackRBCCapMkts 87.95 2/23/2012 Outperform NS $22.35 +72.71% +78.18% -5.48 0 Comment
TrackArgus 92.99 6/9/2011 Outperform NS $18.72 +106.20% +88.81% +17.39 0 Comment
TrackZacks < 20 10/7/2010 Outperform 3M $13.56 +28.69% +16.08% +12.60 2/18/2011 @ $17.45 1 Comment
TrackBrandes < 20 6/30/2010 Outperform NS $7.61 +407.23% +140.26% +266.97 0 Comment
TrackRBCCapMkts 87.95 5/26/2010 Outperform NS $7.34 +80.65% +7.05% +73.60 10/7/2010 @ $13.26 0 Comment
TrackZacks < 20 12/3/2009 Underperform 3M $7.72 +8.94% +2.67% -6.27 1/5/2010 @ $8.41 1 Comment
TrackWedbush 84.35 9/15/2009 Underperform NS $11.08 +12.73% +6.66% -6.06 8/4/2010 @ $12.49 0 Comment
TrackWedbush 84.35 5/13/2009 Outperform NS $7.31 +51.57% +19.00% +32.57 9/15/2009 @ $11.08 0 Comment
TrackCitigroup 94.19 2/14/2008 Outperform NS $21.23 +81.82% +85.02% -3.20 0 Comment
TrackUBS 93.23 10/2/2007 Outperform NS $19.50 -59.28% -36.13% -23.15 7/30/2009 @ $7.94 0 Comment
TrackJMP 86.48 4/30/2007 Outperform NS $23.13 +66.88% +71.75% -4.87 0 Comment
TrackRBCCapMkts 87.95 4/30/2007 Underperform NS $23.16 -12.09% +3.47% +15.56 7/20/2007 @ $20.36 0 Comment
TrackUBS 93.23 1/16/2007 Underperform NS $32.83 -40.60% +8.00% +48.60 10/2/2007 @ $19.50 0 Comment
TrackRBCCapMkts 87.95 10/26/2006 Outperform NS $24.65 -5.88% +7.78% -13.66 4/30/2007 @ $23.20 0 Comment
TrackBroadpointAmTech < 20 10/26/2006 Outperform NS $24.65 -18.30% -0.53% -17.77 4/17/2012 @ $20.14 0 Comment
TrackJimCramer 84.49 3/13/2006 Underperform 3W $21.40 +80.37% +102.46% +22.09 0 Comment

Featured Broker Partners